References
- Archer DF, Furst K, Tipping D, et al. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. CombiPatch Study Group. Obstet. Gynecol 1999;94:498–503.
- Portman DJ, Gass ML, Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women's sexual health and the North American menopause society. Climacteric 2014;17:557–63.
- Labrie F, Martel C, Balser J. Wide distribution of the serum dehydroepiandrosterone and sex steroid levels in postmenopausal women: role of the ovary? Menopause 2011;18:30–43.
- Labrie F, Archer DF, Bouchard C, et al. Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study. Maturitas 2015;81:46–56.
- Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepaindrosterone (prasterone). Menopause 2015;22:950–63.
- Labrie F, Archer DF, Bouchard C, et al. Intravaginal dehydroepiandrosterone (DHEA, Prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282–8.
- Labrie F, Archer DF, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone) a physiological and highly efficient treatment of vaginal atrophy. Menopause 2009;16:907–22.
- Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy and of the genitourinary syndrome of menopause. Menopause 2015; in press.
- Bouchard C, Labrie F, Archer DF, et al. Decreased efficacy of twice-weekly intravaginal dehydroepiandrosterone on vulvovaginal atrophy. Climacteric 2015;18:590–607.
- Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014;17:3–9.
- Bachmann GA, Leiblum SR. Sexuality in sexagenarian women. Maturitas 1991;13:43–50.
- Kao A, Binik YM, Amsel R, et al. Biopsychosocial predictors of postmenopausal dyspareunia: the role of steroid hormones, vulvovaginal atrophy, cognitive-emotional factors, and dyadic adjustment. J Sex Med 2012;9:2066–76.
- Labrie F, Cusan L, Gomez JL, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;111:178–94.
- Labrie F, Cusan L, Gomez JL, et al. Corrigendum to: effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women. J Steroid Biochem Mol Biol 2008;112:169.
- Labrie F, Martel C, Bérubé R, et al. Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens. J Steroid Biochem Mol Biol 2013;138:359–67.
- Labrie F, Archer DF, Bouchard C, et al. Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administration. Menopause 2009;16:897–906.